1
|
Bigi MM, Forrellad MA, García JS, Blanco FC, Vázquez CL, Bigi F. An update on Mycobacterium tuberculosis lipoproteins. Future Microbiol 2023; 18:1381-1398. [PMID: 37962486 DOI: 10.2217/fmb-2023-0088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 08/29/2023] [Indexed: 11/15/2023] Open
Abstract
Almost 3% of the proteins of Mycobacterium tuberculosis (M. tuberculosis), the main causative agent of human tuberculosis, are lipoproteins. These lipoproteins are characteristic of the mycobacterial cell envelope and participate in many mechanisms involved in the pathogenesis of M. tuberculosis. In this review, the authors provide an updated analysis of M. tuberculosis lipoproteins and categorize them according to their demonstrated or predicted functions, including transport of compounds to and from the cytoplasm, biosynthesis of the mycobacterial cell envelope, defense and resistance mechanisms, enzymatic activities and signaling pathways. In addition, this updated analysis revealed that at least 40% of M. tuberculosis lipoproteins are glycosylated.
Collapse
Affiliation(s)
- María M Bigi
- Instituto de Investigaciones Biomédicas, CONICET, Universidad de Buenos Aires, Paraguay 2155 (C1121ABG), Buenos Aires, Argentina
| | - Marina A Forrellad
- Instituto de Biotecnología, CICVyA, Instituto Nacional de Tecnología Agropecuaria, Argentina (INTA), N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
- Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
| | - Julia S García
- Instituto de Biotecnología, CICVyA, Instituto Nacional de Tecnología Agropecuaria, Argentina (INTA), N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
- Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
| | - Federico C Blanco
- Instituto de Biotecnología, CICVyA, Instituto Nacional de Tecnología Agropecuaria, Argentina (INTA), N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
- Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
| | - Cristina L Vázquez
- Instituto de Biotecnología, CICVyA, Instituto Nacional de Tecnología Agropecuaria, Argentina (INTA), N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
- Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
| | - Fabiana Bigi
- Instituto de Biotecnología, CICVyA, Instituto Nacional de Tecnología Agropecuaria, Argentina (INTA), N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
- Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, N. Repetto & de los Reseros, Hurlingham (1686), Buenos Aires, Argentina
| |
Collapse
|
2
|
Belhaouane I, Pochet A, Chatagnon J, Hoffmann E, Queval CJ, Deboosère N, Boidin-Wichlacz C, Majlessi L, Sencio V, Heumel S, Vandeputte A, Werkmeister E, Fievez L, Bureau F, Rouillé Y, Trottein F, Chamaillard M, Brodin P, Machelart A. Tirap controls Mycobacterium tuberculosis phagosomal acidification. PLoS Pathog 2023; 19:e1011192. [PMID: 36888688 PMCID: PMC9994722 DOI: 10.1371/journal.ppat.1011192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Accepted: 01/30/2023] [Indexed: 03/09/2023] Open
Abstract
Progression of tuberculosis is tightly linked to a disordered immune balance, resulting in inability of the host to restrict intracellular bacterial replication and its subsequent dissemination. The immune response is mainly characterized by an orchestrated recruitment of inflammatory cells secreting cytokines. This response results from the activation of innate immunity receptors that trigger downstream intracellular signaling pathways involving adaptor proteins such as the TIR-containing adaptor protein (Tirap). In humans, resistance to tuberculosis is associated with a loss-of-function in Tirap. Here, we explore how genetic deficiency in Tirap impacts resistance to Mycobacterium tuberculosis (Mtb) infection in a mouse model and ex vivo. Interestingly, compared to wild type littermates, Tirap heterozygous mice were more resistant to Mtb infection. Upon investigation at the cellular level, we observed that mycobacteria were not able to replicate in Tirap-deficient macrophages compared to wild type counterparts. We next showed that Mtb infection induced Tirap expression which prevented phagosomal acidification and rupture. We further demonstrate that the Tirap-mediated anti-tuberculosis effect occurs through a Cish-dependent signaling pathway. Our findings provide new molecular evidence about how Mtb manipulates innate immune signaling to enable intracellular replication and survival of the pathogen, thus paving the way for host-directed approaches to treat tuberculosis.
Collapse
Affiliation(s)
- Imène Belhaouane
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Amine Pochet
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Jonathan Chatagnon
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Eik Hoffmann
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Christophe J. Queval
- High Throughput Screening Laboratory, The Francis Crick Institute, London, United Kingdom
| | - Nathalie Deboosère
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Céline Boidin-Wichlacz
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Laleh Majlessi
- Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Paris, France
| | - Valentin Sencio
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Séverine Heumel
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Alexandre Vandeputte
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Elisabeth Werkmeister
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41—UMS 2014—PLBS, Lille, France
| | - Laurence Fievez
- Laboratory of Cellular and Molecular Immunology, GIGA-Research, Liège, Belgium
| | - Fabrice Bureau
- Laboratory of Cellular and Molecular Immunology, GIGA-Research, Liège, Belgium
| | - Yves Rouillé
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - François Trottein
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
| | - Mathias Chamaillard
- Laboratory of Cell Physiology, INSERM U1003, University of Lille, Lille, France
| | - Priscille Brodin
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
- * E-mail: (PB); (AM)
| | - Arnaud Machelart
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, Lille, France
- * E-mail: (PB); (AM)
| |
Collapse
|
3
|
Machelart A, Salzano G, Li X, Demars A, Debrie AS, Menendez-Miranda M, Pancani E, Jouny S, Hoffmann E, Deboosere N, Belhaouane I, Rouanet C, Simar S, Talahari S, Giannini V, Villemagne B, Flipo M, Brosch R, Nesslany F, Deprez B, Muraille E, Locht C, Baulard AR, Willand N, Majlessi L, Gref R, Brodin P. Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. ACS NANO 2019; 13:3992-4007. [PMID: 30822386 PMCID: PMC6718168 DOI: 10.1021/acsnano.8b07902] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 03/01/2019] [Indexed: 05/23/2023]
Abstract
Multi-drug-resistant tuberculosis (TB) is a major public health problem, concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10 000 tablets over a 2-year period. There is a clear need for efficient and better formulated medications. We have previously shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, we report that in addition to being efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Empty pβCD nanoparticles are able to impair Mycobacterium tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonization of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, pβCD provoke macrophage apoptosis, leading to depletion of infected cells, thus creating a lung microenvironment detrimental to Mtb persistence. Taken together, our results suggest that pβCD nanoparticles loaded or not with antibiotics have an antibacterial action on their own and could be used as a carrier in drug regimen formulations effective against TB.
Collapse
Affiliation(s)
- Arnaud Machelart
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Giuseppina Salzano
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Xue Li
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Aurore Demars
- Research
Unit in Microorganisms Biology (URBM), Laboratory of Immunology and
Microbiology, Université de Namur, Narilis, B-5000 Namur, Belgium
| | - Anne-Sophie Debrie
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Mario Menendez-Miranda
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Elisabetta Pancani
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Samuel Jouny
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Eik Hoffmann
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Nathalie Deboosere
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Imène Belhaouane
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Carine Rouanet
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Sophie Simar
- Université
de Lille, Institut Pasteur de Lille, EA 4483, F-59000 Lille, France
| | - Smaïl Talahari
- Université
de Lille, Institut Pasteur de Lille, EA 4483, F-59000 Lille, France
| | - Valerie Giannini
- Institut
Pasteur, Unit for Integrated
Mycobacterial Pathogenomics, Paris, CNRS
UMR 3525, 25 Rue du Dr. Roux, F-75015 Paris, France
| | - Baptiste Villemagne
- Université
de Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France
| | - Marion Flipo
- Université
de Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France
| | - Roland Brosch
- Institut
Pasteur, Unit for Integrated
Mycobacterial Pathogenomics, Paris, CNRS
UMR 3525, 25 Rue du Dr. Roux, F-75015 Paris, France
| | - Fabrice Nesslany
- Université
de Lille, Institut Pasteur de Lille, EA 4483, F-59000 Lille, France
| | - Benoit Deprez
- Université
de Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France
| | - Eric Muraille
- Research
Unit in Microorganisms Biology (URBM), Laboratory of Immunology and
Microbiology, Université de Namur, Narilis, B-5000 Namur, Belgium
- Laboratory
of Parasitology, Faculty of Medicine, Université
Libre de Bruxelles, B-1070 Brussels, Belgium
| | - Camille Locht
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Alain R. Baulard
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Nicolas Willand
- Université
de Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France
| | - Laleh Majlessi
- Institut
Pasteur, Unit for Integrated
Mycobacterial Pathogenomics, Paris, CNRS
UMR 3525, 25 Rue du Dr. Roux, F-75015 Paris, France
| | - Ruxandra Gref
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Priscille Brodin
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| |
Collapse
|
4
|
Chhotaray C, Tan Y, Mugweru J, Islam MM, Adnan Hameed HM, Wang S, Lu Z, Wang C, Li X, Tan S, Liu J, Zhang T. Advances in the development of molecular genetic tools for Mycobacterium tuberculosis. J Genet Genomics 2018; 45:S1673-8527(18)30114-0. [PMID: 29941353 DOI: 10.1016/j.jgg.2018.06.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Mycobacterium tuberculosis, a clinically relevant Gram-positive bacterium of great clinical relevance, is a lethal pathogen owing to its complex physiological characteristics and development of drug resistance. Several molecular genetic tools have been developed in the past few decades to study this microorganism. These tools have been instrumental in understanding how M. tuberculosis became a successful pathogen. Advanced molecular genetic tools have played a significant role in exploring the complex pathways involved in M. tuberculosis pathogenesis. Here, we review various molecular genetic tools used in the study of M. tuberculosis. Further, we discuss the applications of clustered regularly interspaced short palindromic repeat interference (CRISPRi), a novel technology recently applied in M. tuberculosis research to study target gene functions. Finally, prospective outcomes of the applications of molecular techniques in the field of M. tuberculosis genetic research are also discussed.
Collapse
Affiliation(s)
- Chiranjibi Chhotaray
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; University of Chinese Academy of Sciences, Beijing 100049, China
| | - Yaoju Tan
- State Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou 510095, China
| | - Julius Mugweru
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; University of Chinese Academy of Sciences, Beijing 100049, China; Department of Biological Sciences, University of Embu, P.O Box 6 -60100, Embu, Kenya
| | - Md Mahmudul Islam
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; University of Chinese Academy of Sciences, Beijing 100049, China
| | - H M Adnan Hameed
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; University of Chinese Academy of Sciences, Beijing 100049, China
| | - Shuai Wang
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; University of Chinese Academy of Sciences, Beijing 100049, China
| | - Zhili Lu
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
| | - Changwei Wang
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
| | - Xinjie Li
- State Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou 510095, China
| | - Shouyong Tan
- State Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou 510095, China
| | - Jianxiong Liu
- State Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou 510095, China.
| | - Tianyu Zhang
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; University of Chinese Academy of Sciences, Beijing 100049, China.
| |
Collapse
|
5
|
Insights from the Genome Sequence of Mycobacterium lepraemurium: Massive Gene Decay and Reductive Evolution. mBio 2017; 8:mBio.01283-17. [PMID: 29042494 PMCID: PMC5646247 DOI: 10.1128/mbio.01283-17] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Mycobacterium lepraemurium is the causative agent of murine leprosy, a chronic, granulomatous disease similar to human leprosy. Due to the similar clinical manifestations of human and murine leprosy and the difficulty of growing both bacilli axenically, Mycobacterium leprae and M. lepraemurium were once thought to be closely related, although it was later suggested that M. lepraemurium might be related to Mycobacterium avium. In this study, the complete genome of M. lepraemurium was sequenced using a combination of PacBio and Illumina sequencing. Phylogenomic analyses confirmed that M. lepraemurium is a distinct species within the M. avium complex (MAC). The M. lepraemurium genome is 4.05 Mb in length, which is considerably smaller than other MAC genomes, and it comprises 2,682 functional genes and 1,139 pseudogenes, which indicates that M. lepraemurium has undergone genome reduction. An error-prone repair homologue of the DNA polymerase III α-subunit was found to be nonfunctional in M. lepraemurium, which might contribute to pseudogene formation due to the accumulation of mutations in nonessential genes. M. lepraemurium has retained the functionality of several genes thought to influence virulence among members of the MAC. Mycobacterium lepraemurium seems to be evolving toward a minimal set of genes required for an obligatory intracellular lifestyle within its host, a niche seldom adopted by most mycobacteria, as they are free-living. M. lepraemurium could be used as a model to elucidate functions of genes shared with other members of the MAC. Its reduced gene set can be exploited for studying the essentiality of genes in related pathogenic species, which might lead to discovery of common virulence factors or clarify host-pathogen interactions. M. lepraemurium can be cultivated in vitro only under specific conditions and even then with difficulty. Elucidating the metabolic (in)capabilities of M. lepraemurium will help develop suitable axenic media and facilitate genetic studies.
Collapse
|
6
|
Song OR, Deboosere N, Delorme V, Queval CJ, Deloison G, Werkmeister E, Lafont F, Baulard A, Iantomasi R, Brodin P. Phenotypic assays for Mycobacterium tuberculosis infection. Cytometry A 2017; 91:983-994. [PMID: 28544095 DOI: 10.1002/cyto.a.23129] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2016] [Revised: 03/23/2017] [Accepted: 04/13/2017] [Indexed: 12/13/2022]
Abstract
Tuberculosis (TB) is still a major global threat, killing more than one million persons each year. With the constant increase of Mycobacterium tuberculosis strains resistant to first- and second-line drugs, there is an urgent need for the development of new drugs to control the propagation of TB. Although screenings of small molecules on axenic M. tuberculosis cultures were successful for the identification of novel putative anti-TB drugs, new drugs in the development pipeline remains scarce. Host-directed therapy may represent an alternative for drug development against TB. Indeed, M. tuberculosis has multiple specific interactions within host phagocytes, which may be targeted by small molecules. In order to enable drug discovery strategies against microbes residing within host macrophages, we developed multiple fluorescence-based HT/CS phenotypic assays monitoring the intracellular replication of M. tuberculosis as well as its intracellular trafficking. What we propose here is a population-based, multi-parametric analysis pipeline that can be used to monitor the intracellular fate of M. tuberculosis and the dynamics of cellular events such as phagosomal maturation (acidification and permeabilization), zinc poisoning system or lipid body accumulation. Such analysis allows the quantification of biological events considering the host-pathogen interplay and may thus be derived to other intracellular pathogens. © 2017 International Society for Advancement of Cytometry.
Collapse
Affiliation(s)
- Ok-Ryul Song
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| | - Nathalie Deboosere
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| | - Vincent Delorme
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France.,Tuberculosis Research Laboratory, Institut Pasteur Korea, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Korea
| | - Christophe J Queval
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| | - Gaspard Deloison
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| | - Elisabeth Werkmeister
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| | - Frank Lafont
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| | - Alain Baulard
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| | - Raffaella Iantomasi
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| | - Priscille Brodin
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000, France
| |
Collapse
|
7
|
Gonzalez-Perez M, Murcia M, Parra-Lopez C, Blom J, Tauch A. Deciphering the virulence factors of the opportunistic pathogen Mycobacterium colombiense. New Microbes New Infect 2016; 14:98-105. [PMID: 27818776 PMCID: PMC5072152 DOI: 10.1016/j.nmni.2016.09.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 08/02/2016] [Accepted: 09/06/2016] [Indexed: 11/17/2022] Open
Abstract
Mycobacterium avium complex (MAC) contains clinically important nontuberculous mycobacteria worldwide and is the second largest medical complex in the Mycobacterium genus after the Mycobacterium tuberculosis complex. MAC comprises several species that are closely phylogenetically related but diverse regarding their host preference, course of disease, virulence and immune response. In this study we provided immunologic and virulence-related insights into the M. colombiense genome as a model of an opportunistic pathogen in the MAC. By using bioinformatic tools we found that M. colombiense has deletions in the genes involved in p-HBA/PDIM/PGL, PLC, SL-1 and HspX production, and loss of the ESX-1 locus. This information not only sheds light on our understanding the virulence mechanisms used by opportunistic MAC pathogens but also has great potential for the designing of species-specific diagnostic tools.
Collapse
Affiliation(s)
- M.N. Gonzalez-Perez
- Microbiology Department, School of Medicine, National University of Colombia, Bogotá, Colombia
- Center for Biotechnology (CeBiTec), Bielefeld University, Bielefeld, Germany
- Corresponding author: M. N. Gonzalez-Perez, Microbiology Department, School of Medicine, National University of Colombia, Bogotá, ColombiaMicrobiology DepartmentSchool of MedicineNational University of ColombiaBogotáColombia
| | - M.I. Murcia
- Microbiology Department, School of Medicine, National University of Colombia, Bogotá, Colombia
| | - C. Parra-Lopez
- Microbiology Department, School of Medicine, National University of Colombia, Bogotá, Colombia
| | - J. Blom
- Bioinformatics and Systems Biology, Justus Liebig University Giessen, Giessen, Germany
| | - A. Tauch
- Microbiology Department, School of Medicine, National University of Colombia, Bogotá, Colombia
- Center for Biotechnology (CeBiTec), Bielefeld University, Bielefeld, Germany
| |
Collapse
|
8
|
Deboosère N, Iantomasi R, Queval CJ, Song OR, Deloison G, Jouny S, Debrie AS, Chamaillard M, Nigou J, Cohen-Gonsaud M, Locht C, Brodin P, Veyron-Churlet R. LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. Cell Microbiol 2016; 19. [PMID: 27220037 PMCID: PMC5217060 DOI: 10.1111/cmi.12619] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Revised: 05/10/2016] [Accepted: 05/12/2016] [Indexed: 01/19/2023]
Abstract
Mycobacterium tuberculosis produces several bacterial effectors impacting the colonization of phagocytes. Here, we report that the putative lipoprotein LppM hinders phagocytosis by macrophages in a toll-like receptor 2-dependent manner. Moreover, recombinant LppM is able to functionally complement the phenotype of the mutant, when exogenously added during macrophage infection. LppM is also implicated in the phagosomal maturation, as a lppM deletion mutant is more easily addressed towards the acidified compartments of the macrophage than its isogenic parental strain. In addition, this mutant was affected in its ability to induce the secretion of pro-inflammatory chemokines, interferon-gamma-inducible protein-10, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1α. Thus, our results describe a new mycobacterial protein involved in the early trafficking of the tubercle bacillus and its manipulation of the host immune response.
Collapse
Affiliation(s)
- Nathalie Deboosère
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Raffaella Iantomasi
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Christophe J Queval
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Ok-Ryul Song
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Gaspard Deloison
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Samuel Jouny
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Anne-Sophie Debrie
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Mathias Chamaillard
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Jérôme Nigou
- Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse CNRS, Toulouse, F-31077, France
| | - Martin Cohen-Gonsaud
- Centre de Biochimie Structurale, CNRS UMR 5048, Inserm U1054, Université de Montpellier, Montpellier, F-34090, France
| | - Camille Locht
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Priscille Brodin
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| | - Romain Veyron-Churlet
- Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, F-59000, France.,CNRS, UMR 8204, Lille, F-59000, France.,Inserm U1019, Lille, F-59000, France.,CHU Lille, Lille, F-59000, France.,Institut Pasteur de Lille, Lille, F-59000, France
| |
Collapse
|